LL-37 (Cathelicidin / hCAP18 fragment)
Endogenous cathelicidin antimicrobial peptide — targeted pathogen elimination without microbiome disruption, increasingly investigated for post-viral recovery and oral health.
At a glance
What it is: Endogenous cathelicidin antimicrobial peptide — targeted pathogen elimination without microbiome disruption, increasingly investigated for post-viral recovery and oral health..
Primary research applications:
- Topical antimicrobial wound healing — chronic venous ulcers
- Oral and periodontal health research
- Post-viral recovery and immune resilience contexts
- Antimicrobial alternative to antibiotics — research interest in microbiome-sparing pathogen elimination
- Inflammatory and immune signaling research
Editorial summary: LL-37 is the principal human cathelicidin antimicrobial peptide — an endogenous effector of innate immunity expressed in gut, skin, oral cavity, and respiratory tissue. The community and research interest centers on a meaningful pharmacologic angle: targeted pathogen elimination without the broad microbiome disruption that antibiotics produce. Unlike antibiotics that affect both pathogens and commensal organisms, LL-37 has selective activity against pathogenic bacteria, fungi, and enveloped viruses with relative sparing of established commensal microbiota. 2026 research has extended the framework into post-viral recovery (including long-COVID contexts) and oral health applications (gingivitis, periodontitis, oral microbiome modulation). The honest framing: topical wound-healing evidence is the established translational story; the broader antimicrobial-without-microbiome-disruption framing is mechanistically supported but clinically still being characterized.
- Class / structure
- 37-amino-acid cationic alpha-helical peptide (cleaved from hCAP18)
- Half-life
- Tissue-context dependent; minutes in plasma
- First described
- 1995 (cloning of human CAP18 cDNA)
- Regulatory status
- Not FDA-approved; topical analogs in development
What is LL-37?
LL-37 is a 37-amino-acid cationic alpha-helical peptide derived from hCAP18 by proteinase 3 cleavage. Its name derives from the leucine-leucine residues at the N-terminus and its 37-amino-acid length.
Discovery and development
LL-37 is the C-terminal active fragment cleaved from the precursor protein hCAP18 (human cathelicidin antimicrobial protein, 18 kDa), the only cathelicidin in the human genome. It was first cloned in 1995 (Cowland et al.) and has since become one of the most studied antimicrobial peptides in mammalian biology, expressed by neutrophils, epithelial cells, and several other cell types as part of the innate immune barrier.
Mechanism of action
LL-37 has multiple, partly overlapping activities:
- Direct antimicrobial action — disrupts microbial membranes, especially bacteria and enveloped viruses.
- Immunomodulation — modulates dendritic cell function, neutrophil recruitment, and cytokine signaling.
- Wound healing — promotes keratinocyte migration, angiogenesis, and re-epithelialization.
The dual antimicrobial / immunomodulatory profile is part of why cathelicidins have attracted such broad translational interest.[1]
Pharmacokinetics
LL-37 is generated locally at sites of infection or injury, with rapid plasma turnover that reflects its role as a tissue-resident effector rather than a circulating hormone. Therapeutic interest centers on local delivery — topical, inhaled, or wound-bed application — rather than systemic dosing.
What the research shows
The peer-reviewed literature on LL-37 is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Has direct antimicrobial activity in vitro | Extensive literature | Supported |
| Promotes wound healing in topical applications | Animal models and small human trials | Supported |
| Is a generally safe systemic therapy | Systemic toxicity profile is incompletely characterized | Uncertain |
| Replaces antibiotics | Adjunctive in research; not a clinical substitute | Unsupported |
Reported user experiences
How the research describes administration
Most published research uses topical or local formulations. Systemic peptide formulations are limited by short plasma half-life and the molecule's potent immunomodulatory profile.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
LL-37 is one of the most-studied antimicrobial peptides in human innate immunity, with the strongest translational evidence in topical wound healing and growing community interest in post-viral recovery and oral health applications. The mechanism story that distinguishes LL-37 from conventional antibiotics — targeted pathogen elimination without broad microbiome disruption — is genuinely mechanistically supported and clinically interesting, though formal head-to-head comparison data with antibiotic protocols is limited.
LL-37 appears in the Gut Healing & Mucosal Barrier Stack as a complementary antimicrobial component alongside KPV, BPC-157, and other gut-focused compounds — the rationale being microbiome-sparing pathogen control in dysbiotic gut contexts. The 2025-2026 research extension into post-viral recovery (long-COVID) and oral health (periodontitis, oral dysbiosis) represents the more interesting emerging applications. Community use of LL-37 in research-peptide contexts is more limited than for some other healing peptides — the molecule's potent immunomodulatory profile and limited oral bioavailability make casual self-administration less established. Topical and oral-cavity applications under qualified-practitioner supervision are the most-defensible current use cases.
Frequently asked questions
Is LL-37 the same thing as cathelicidin?
LL-37 is the active fragment cleaved from hCAP18, the human cathelicidin precursor. "Cathelicidin" can refer to the broader gene family or, in human contexts, specifically to LL-37.
Does vitamin D affect LL-37?
Yes. The vitamin D receptor regulates cathelicidin expression in monocytes and keratinocytes — one mechanism by which vitamin D status connects to innate immunity.
References
- Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006;1758(9):1408-1425. https://pubmed.ncbi.nlm.nih.gov/16716248/
- Gronberg A, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014;22(5):613-621. https://pubmed.ncbi.nlm.nih.gov/25041618/